Welcome to #1 DIGITAL HEALTH NEWS Portal

Evaluating Diabetes Self-Help Tools

There is an increasing amount of self-help tools among people with diabetes. They use apps, social media and various cloud-based solutions to cope. Now, e-health researchers will make guidelines for evaluating the apps and online resources they use.

Read more ...

Advanced ICU Care Extends Contract with Philips to Deliver Tele-ICU Care to Partner Hospitals in the U.S.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that Advanced ICU Care, the largest provider of tele-ICU care in the U.S., has extended its collaboration with Philips by signing a new 12-year agreement. A Philips tele-ICU customer since 2006, Advanced ICU Care will leverage Philips' tele-ICU technology to help power nine virtual care hubs, monitoring nearly 1,000 ICU beds across the U.S.

Read more ...

Mobile Health Applications Put the Personal Data of Millions of Users at Risk

80% of the most popular health applications available on Android do not comply with standards intended to prevent the misuse and dissemination of their users' data. This is the finding of a European study started in 2016 and involving Agustí Solanas, head of the Smart Health research group at the URV's Department of Computer Engineering and Mathematics, and researchers from the University of Piraeus (Greece) headed by Constantinos Patsakis.

Read more ...

Allscripts to Sell OneContent Business to Hyland

Allscripts (NASDAQ:MDRX) has signed a definitive agreement to sell its OneContent business to Hyland Software, Inc., a leading provider of content services solutions to the healthcare industry and beyond. The deal is expected to close in the second quarter once customary closing conditions are satisfied.

Read more ...

Lung Cancer Drug Resistance Explained by Computer Simulations

Scientists from the Universities of Bristol and Parma, Italy, have used molecular simulations to understand resistance to osimertinib - an anticancer drug used to treat types of lung cancer. Osimertinib binds tightly to a protein, epidermal growth factor receptor (EGFR), which is overexpressed in many tumours. EGFR is involved in a pathway that signals for cell proliferation, and so is a target for drugs. Blocking the action of EGFR (inhibiting it) can switch it off, and so is a good way to treat the disease.

Read more ...

FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients

Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

Read more ...

Cancer-Fighting Nanorobots Programmed to Seek and Destroy Tumors

In a major advancement in nanomedicine, Arizona State University (ASU) scientists, in collaboration with researchers from the National Center for Nanoscience and Technology (NCNST), of the Chinese Academy of Sciences, have successfully programmed nanorobots to shrink tumors by cutting off their blood supply.

Read more ...

Open Call SC1-HCC-04-2018: Digital Health and Care Services - Support for Strategy and (Early) Adoption

Health and care service providers and users are increasingly facing complex decisions when exploring and investing in new health and care solutions. There is a need to support cross-border cooperation in preparation of procurement of research and innovative digital solutions, including on how to balance innovation risks with improved outcomes.

Read more ...

Biosensors Will Be Inexpensive, Do More, Go Everywhere

When it comes to biometric sensors, human skin isn't an ally. It's an obstacle. The University of Cincinnati is developing cutting-edge methods to overcome this barrier without compromising the skin and its ability to prevent infection and dehydration. By making better noninvasive tests, researchers can open up enormous opportunities in medicine and the fitness industry.

Read more ...

Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhoneTM and AndroidTM

Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones(2) (both iPhone and Android). People with diabetes living in Europe and using the FreeStyle® Libre system(3) are now able to access glucose data directly from their smartphones, eliminating the need to carry the separate FreeStyle Libre reader(4) (a handheld device used to scan the FreeStyle Libre sensor to get a glucose result).

Read more ...